Introduction {#S0001}
============

Adenocarcinoma of esophagogastric junction (AEG) emerged and has rapidly increased in prevalence in Western countries over recent decades.[@CIT0001] According to the 8th edition of the American Joint Committee on Cancer (AJCC) cancer TNM staging system, Siewert type 2 and 3 AEG should be classified as gastric cancer.[@CIT0002] Gastric cancer greatly contributes to the global cancer burden,[@CIT0003] as it is the third leading cause of cancer deaths worldwide,[@CIT0004] which is almost identical to the situation in China.[@CIT0005] Due to their high rates of recurrences, the prognosis of patients with AEG or gastric cancer remains poor even after curative surgery,[@CIT0006],[@CIT0007] and the postoperative 5-year survival after surgery is less than 40%.[@CIT0008],[@CIT0009] Therefore, it would be helpful to design a scoring system to target long-term outcomes for AEG patients, as well as guide treatment and follow-up.

Accumulating evidence has revealed that systemic immune-inflammation plays pivotal roles in carcinogenesis and tumour progression. The neutrophil to lymphocyte ratio (NLR),[@CIT0010] platelet to lymphocyte ratio (PLR),[@CIT0011] prognostic nutritional index (PNI),[@CIT0012] and albumin to globulin ratio (AGR)[@CIT0013],[@CIT0014] are inflammation-based hallmarks that have been proved to be associated with worse prognosis in various human malignancies. Moreover, no studies have validated the prognostic value of an integrated scoring system consisting inflammation-based hallmarks in AEG. Consequently, the current study aimed to determine whether the combination of the PNI and AGR could better predict OS of patients after radical surgery for AEG.

Patients and methods {#S0002}
====================

This study was approved by the Ethical Committee of Harbin Medical University Cancer Hospital and conducted in accordance with the Declaration of Helsinki.

Study population and follow-up {#S0002-S2001}
------------------------------

This retrospective study involved 215 consecutive patients who underwent radical open surgery (R0, D2) for S3-AEG in Harbin Medical University Cancer Hospital from January 1993 to January 2013. Study approval was granted by the local institution review board, and all patients involved provided written informed consent. AEG diagnoses were postoperatively confirmed by pathologists according to the current AJCC classification. Neither chemotherapy nor radiotherapy was used for treatment in this study. Patients who experienced the following situations were excluded: 1) intestinal obstruction, active bleeding, autoimmune diseases or other inflammatory disorders; 2) missing data; 3) preoperative blood product transfusion; 4) having other malignancies; and 5) AEG-unrelated death. Each AEG patient was followed up via telephone and an outpatient visit until January 2018 or their date of death. OS was measured as the interval from the date of surgery to death or latest follow-up.

Data collection {#S0002-S2002}
---------------

The clinical data and baseline demographics of the patients were collected from the Harbin Medical University Cancer Hospital CRC database and chart review. Blood tests were measured within one week before surgery. Serum carcinoembryonic antigen (CEA), C-reactive protein (CRP), carbohydrate antigen levels and hepatitis B virus (HBV) infection status were not routine tests at diagnosis and were excluded in this retrospective study.

Prognostic scoring system {#S0002-S2003}
-------------------------

The AGR was defined as the ratio between the serum albumin concentration (g/L) and the serum globulin concentration (g/L). In the same way, the PLR was defined as the ratio between the absolute platelet count (×10^9^/L) and the absolute lymphocyte count (×10^9^/L), while the NLR was defined as the ratio between the absolute neutrophil count (×10^9^/L) and the absolute lymphocyte count (×10^9^/L).

The prognostic nutritional index (PNI) was calculated from the serum albumin concentration and absolute lymphocyte count: serum albumin concentration (g/L) +5× total lymphocyte count (×10^9^/L).[@CIT0015],[@CIT0016]

The optimal cutoff points for the preoperative AGR and PNI were selected using receiver operating characteristic (ROC) curve analysis. The optimal cutoff points for age, tumour size, and the preoperative NLR and PLR were according to the median values.

AGR or PNI values less than their cutoff points were assigned a score of 0; otherwise, they were assigned a score of 1. The final prognostic score for AGR-PNI was calculated as the AGR score + the PNI score.

Statistical analyses {#S0002-S2004}
--------------------

All data analyses were conducted with the SPSS version 19.0 software (IBM Corporation, Armonk, NY, USA). Two-sided *P*-values \<0.05 were considered to be statistically significant. The relationships between the prognostic scores (AGR-PNI) and other clinicopathological parameters were elucidated with a chi-square test. Kaplan-Meier curves were constructed for survival analysis. ROC curve analyses for OS were carried out to determine the optimal cutoff values of the AGR and PNI, and the AUC values were used to compare the predictive ability of the prognosticators. Multivariate analyses were performed with the Cox hazards regression model based on the risk factors filtered by univariate analyses to determine independent factors for prognosis.

Results {#S0003}
=======

Patient characteristics {#S0003-S2001}
-----------------------

Of 215 S3-AEG patients, 182 (84.7%) were male and 33 (15.3%) were female. The patients' median age was 62 years, ranging from 30 to 85. The cut-off values of age, tumour size, and the preoperative NLR and PLR were 62 years, 5.0 cm, 2.2, and 130.8, respectively. The number of well-differentiated cancer grade cases was 99. According to the 8th edition of AJCC, 20 patients were in stage I, 67 were in stage II, and 128 were in stage III. Among these patients, 9 were in T1, 15 were in T2, 19 were in T3, 172 were in T4, and 134 had lymph node metastasis. The median follow-up period in this study was 22 months, ranging from 1.5 to 134 months. Overall, 144 patients were confirmed to be dead at the end of the follow-up. The 3-year survival rate and 5-year survival rate were 35.35% and 20.47%, respectively. The numbers of cases with different AGR-PNI scores are shown in [Table 1](#T0001){ref-type="table"}.Table 1Univariate and multivariate analyses of the clinicopathological characteristics for overall survival in 215 patients with S3-AEGCharacteristicsPatients (%)OS (months)UnivariateMultivariate\[mean (95% CI)\]HR 95% CI*P*-valueHR 95% CI*P*-valueAge (years)0.977 (0.701--1.363)0.892 \<6298 (45.6%)48.7 (37.8--59.6) ≥62117 (54.4%)50.1 (40.9--59.4)Gender1.231 (0.781--1.940)0.371 Male182 (84.7%)50.6 (43.1--58.0) Female33 (15.3%)53.7 (34.7--72.8)Tumour size (cm)1.473 (1.032--2.103)**0.033**0.969 (0.667--1.406)0.867 \<5.073 (34.0%)57.6 (46.3--68.8) ≥5.0142 (66.0%)45.4 (36.9--53.8)Differentiation1.258 (0.903--1.751)0.174 Poor116 (54.0%)44.2 (36.1--52.4) Well99 (46.0%)55.3 (44.5--66.2)Pathological T stage1.512 (1.159--1.973)**0.002**0.843 (0.001--1.911)0.957 T19 (4.2%)98.4 (90.3--106.4) T215 (7.0%)65.7 (41.0--90.5) T319 (8.8%)30.5 (19.3--41.7) T4172 (80.0%)46.3 (38.8--53.8)Lymph node metastasis0.411 (0.283--0.595)**\<0.001**0.469 (0.320--0.688)**\<0.001** Negative81 (37.7%)69.8 (58.8--80.8) Positive134 (62.3%)37.8 (30.0--45.7)pTNM stage2.246 (1.571--3.209)**\<0.001** I and II87 (40.5%)68.3 (17.7--118.9) III128 (59.5%)18.7 (15.3--22.0)AGR-PNI0.637 (0.503--0.807)**\<0.001**0.613 (0.226--0.923)**\<0.001** 039 (18.1%)14.5 (9.8--19.3) 1107 (49.8%)28.3 (21.4--35.0) 269 (32.1%)56.0 (23.6--89.6)PLR1.256 (0.905--1.742)0.173 \<130.8107 (49.8%)54.0 (43.9--64.0) ≥130.8108 (50.2%)46.2 (36.5--55.9)NLR1.118 (0.805--1.550)0.506 \<2.2106 (49.3%)51.9 (42.0--61.9) ≥2.2109 (50.7%)48.8 (38.9--58.7)[^2]

Optimal cutoff values {#S0003-S2002}
---------------------

Based on the ROC curve analyses for OS, the cutoff values were defined as 1.72 for the AGR (sensitivity, 52.1; specificity, 70.1; area under the curve (AUC), 0.600; *P*=0.017) and 45.55 for the PNI (sensitivity, 88.7; specificity, 70.8; AUC, 0.574; *P*=0.079) ([Figure 1](#F0001){ref-type="fig"}).Figure 1Receiver operating characteristic curve for the (**A**) albumin-to-globulin ratio and (**B**) prognostic nutritional index.

Univariate and multivariate analyses {#S0003-S2003}
------------------------------------

The results of univariate analyses showed that the T stage (*P*=0.002), lymph node metastasis (*P*=0.071), TNM stage (*P*\<0.001), tumour size (*P*=0.033) and AGR-PNI score (*P*\<0.001) were statistically significantly associated with AEG patients' OS ([Table 1](#T0001){ref-type="table"}). Because pTNM stage was too strong related with T and N, it was not further analysed by multivariate analysis. Then, the 4 variables were further analysed by multivariate analyses, and the results showed that the N stage (HR: 0.469, 95% CI: 0.320--0.688, *P*\<0.001) and AGR-PNI score (HR: 0.613, 95% CI: 0.226--0.923, *P*\<0.001) were independent prognosticators ([Table 1](#T0001){ref-type="table"}).

Prognostic scores and survival {#S0003-S2004}
------------------------------

Kaplan-Meier analyses revealed that the 5-year survival rates of AEG patients with AGR-PNI scores of 2, 1, and 0 were 36.2%, 13.1%, and 12.8%, respectively (*P*=0.001; [Figure 2A](#F0002){ref-type="fig"}). Patients with an AGR-PNI score of 2 had significantly longer mean OS than patients with an AGR-PNI score of 1 or 0 (56.0 vs 28.3 and 14.5 months; *P*=0.001; [Figure 2A](#F0002){ref-type="fig"}). The predictive abilities of the AGR-PNI score were dramatic in stage I + II (*P*=0.043; [Figure 2B](#F0002){ref-type="fig"}) and in stage III (*P*=0.003; [Figure 2C](#F0002){ref-type="fig"}). The mean OS was longer in stage III patients with an AGR-PNI score of 2 (24.0 months) than in stage I + II patients with an AGR-PNI score of 0 (22.0 months) (*P*=0.643; [Figure 2D](#F0002){ref-type="fig"}).Figure 2Kaplan-Meier overall survival curves of 5-year survival rates for 215 patients with S3-AEG undergoing curative resection stratified according to the AGR-PNI score. (**A**) Patients with either stage I, II or III S3-AEG. (**B**) Patients with stage I or II S3-AEG. (**C**) Patients with stage III S3-AEG. (**D**) Stage III S3-AEG patients with an AGR-PNI score of 2, and stage I + II S3-AEG patients with a AGR-PNI score of 0.

Prognostic scores and clinical data {#S0003-S2005}
-----------------------------------

AGR-PNI scores were significantly associated with age (*P*=0.019), tumour size (*P*=0.016), PLR scores (*P*=0.032) and NLR scores (*P*=0.004) ([Table 2](#T0002){ref-type="table"}).Table 2Relationships between AGR-PNI and the clinicopathological characteristics of 215 S3-AEG patientsCharacteristicsAGR-PNI*P*-value012Age (years)**0.019** \<6216 (7.44%)41 (19.07%)41 (19.07%) ≥6223 (10.70%)66 (30.70%)28 (13.02%)Gender0.056 Male30 (13.95%)88 (40.93%)64 (29.77%) Female9 (4.19%)19 (8.84%)5 (2.32%)Tumour size (cm)**0.016** \<5.07 (3.26%)35 (16.28%)31 (14.42%) ≥5.032 (14.88%)72 (33.49%)38 (17.67%)Differentiation0.154 Poor21 (9.77%)64 (29.77%)31 (14.42%) Well18 (8.37%)43 (20.00%)38 (17.67%)T stage0.871 T11 (0.46%)5 (2.32%)3 (1.39%) T22 (0.94%)7 (3.26%)6 (2.79%) T33 (1.39%)12 (5.58%)4 (1.86%) T433 (15.35%)83 (38.61%)56 (26.05%)Lymph node metastasis0.625 Negative13 (6.05%)39 (18.14%)29 (13.49%) Positive26 (12.09%)68 (31.63%)40 (18.60%)pTNM stage0.607 I and II16 (7.44%)40 (18.60%)31 (14.42%) III23 (10.70%)67 (31.17%)38 (17.67%)NLR**0.004** \<2.210 (4.65%)57 (26.51%)39 (18.14%) ≥2.229 (13.49%)50 (23.26%)30 (13.95%)PLR**0.032** \<130.812 (5.58%)58 (26.98%)37 (17.21%) ≥130.827 (12.56%)49 (22.79%)32 (14.88%)[^3]

Predictive ability of prognosticators {#S0003-S2006}
-------------------------------------

The results of the comparison of AUC values indicated that the predictive ability of the AGR-PNI scores ([Table 3](#T0003){ref-type="table"}, AUC, 0.653, 95% CI: 0.576--0.729, *P*\<0.001) was better than that of other parameters ([Figure 3](#F0003){ref-type="fig"}).Table 3Area under the ROC curves of the tumour size and of the NLR, PLR, and AGR-PNI scoresCharacteristicsArea under the ROC curve (95% CI)P-valueTumour size (cm)0.551 (0.469--0.684)0.220NLR0.510 (0.428--0.593)0.803PLR0.539 (0.487--0.634)0.112AGR-PNI0.653 (0.500--0.648)**\<0.001**[^4][^5] Figure 3Area under the receiver operating characteristic curves of tumour size and of the NLR, PLR, and AGR-PNI scores.**Abbreviations:** AGR, albumin-to-globulin ratio; PNI, prognostic nutritional index; PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio.

Discussion {#S0004}
==========

Mounting evidence reveals that a poor nutritional status and systemic immune-inflammation correlate with a grave prognosis in a variety of malignancies. In this study, we assessed the prognostic relevance of the nutrition-inflammation-based AGR-PNI score in S3-AEG patients after radical surgery. Our results suggested that the AGR-PNI score could serve as independent prognosticators for S3-AEG better than other parameters.

The inflammatory cells in the tumour microenvironment have been found to play crucial roles in carcinogenesis, facilitation of tumour cell proliferation, invasion and migration.[@CIT0017]--[@CIT0019] Previous studies have highlighted that hypoalbuminemia is associated with inflammatory mediators and increased tumour-related mortality in several malignancies.[@CIT0020]--[@CIT0023] Globulin could reflect cumulative exposure to various proinflammatory cytokines, such as interleukins and tumour necrosis factor α.[@CIT0024]

Various recent studies have indicated that low PNI and AGR scores and high PLR and NLR scores are associated with poor prognosis in various types of malignancies.[@CIT0013],[@CIT0014],[@CIT0025]--[@CIT0030] Nevertheless, these prognosticators may not comprehensively predict tumour patients' OS. Herein, our study evaluated the prognostic value of integrated prognosticators in S3-AEG patients.

In this study, we found that the AGR-PNI score was significantly negatively correlated with AEG patients' age and tumour size. Our data were consistent with previous studies, in which nutrition-inflammation-based prognostic indicators were dramatically associated with tumour progression.[@CIT0012],[@CIT0030],[@CIT0031] Our Kaplan-Meier analyses revealed that the AGR-PNI score positively correlated with AEG patients' OS (*P*=0.001). The mean OS was longer in stage III patients with an AGR-PNI score of 2 (24.0 months) than in stage I + II patients with an AGR-PNI score of 0 (22.0 months). Although there was no statistical significance (*P*=0.643; [Figure 2D](#F0002){ref-type="fig"}), the difference was large enough to distinguish AEG patients at high risk better than the TNM stage alone. Moreover, multivariate analyses showed that the AGR-PNI score was an independent prognosticator for AEG. In addition, the prognostic value of the AGR-PNI score was verified in stage I + II patients (*P*=0.043) and in stage III patients (*P*=0.003).

Our findings also demonstrated that other integrated indicators, including the PLR score (*P*=0.173) and NLR score (*P*=0.506), failed to be independent prognostic predictors of OS for AEG in univariate analyses. These results contradicted previous studies that the PLR and NLR scores were independent predictors of OS for gastric cancer.[@CIT0032] The AUC value of the AGR-PNI score was higher than that of other integrated indicators we tested in this study (0.653; *P*\<0.001), which revealed that the AGR-PNI score had a better prognostic value than other integrated indicators.

Nonetheless, we could not ignore the limitations of the current study, which might have affected our results. This retrospective study was initiated by a single centre, which was the major limitation. However, the validity of our results came from a large database with detailed information on tumour characteristics and treatment, which could investigate the prognostic value of integrated nutritional and inflammatory indicators.

Conclusion {#S0005}
==========

We found that the AGR-PNI score was an independent prognostic predictor of OS for AEG. A low AGR-PNI score was associated with poor prognosis in S3-AEG patients.
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